SCHEMBL1176017

SCHEMBL1176017

CNc1nc(-c2ccc(C)o2)c2c(N)c(C(N)=O)sc2n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 2/20 0.60
BRAF P15056 13/20 0.59
PDE4A P27815 12/20 0.59
PDE4B Q07343 12/20 0.59
PDE4C Q08493 12/20 0.59
PDE4D Q08499 12/20 0.59
HPGD P15428 2/20 0.56
MAPT P10636 2/20 0.56
MEN1 O00255 1/20 0.56
ALDH1A1 P00352 1/20 0.56
GAA P10253 1/20 0.56
KMT2A Q03164 1/20 0.56
IKBKB O14920 3/20 0.46
CHUK O15111 1/20 0.46
PRKACA P17612 1/20 0.46
PRKACG P22612 1/20 0.46
PRKACB P22694 1/20 0.46
BTK Q06187 1/20 0.46
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1176342 0.87 LIMK1 (0.60) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL1176638 0.86 LIMK1 (0.50) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL1176639 0.86 LIMK1 (0.50) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL1176603 0.86 BRAF (0.55) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL3406840 0.84 LIMK1 (0.42) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL1176524 0.83 BRAF (0.50) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL12871394 0.83 BRAF (0.58) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL1176597 0.83 LIMK1 (0.59) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL2132227 0.83 LIMK1 (0.56) LIMK1BRAFPDE4APDE4BPDE4C
SCHEMBL1176165 0.83 LIMK1 (0.56) LIMK1HPGDMAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102015724-A Thienopyrimidines MERCK PATENT GMBH 2011-04-13 CN claimed
US-20110028472-A1 THIENOPYRIMIDINES MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-02-03 US claimed
US-20110028472-A1 THIENOPYRIMIDINES MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-02-03 US disclosed
US-20110028472-A1 THIENOPYRIMIDINES MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-02-03 US disclosed
US-20110028472-A1 THIENOPYRIMIDINES MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028472-A1 THIENOPYRIMIDINES TGFBR1, TYMP, TGFBR2 LIMK1 1626/4885BRAF 183/4885PDE4A 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.